Mantle cell lymphoma characterized by numerous diffuse polypoid lesions along the entire digestive tract: A case report

Cheng,Siqi; Yang,Li; Wang,Xiangyang

doi:10.3892/ol.2024.14496

Mantle cell lymphoma characterized by numerous diffuse polypoid lesions along the entire digestive tract: A case report

Authors:
- Siqi Cheng
- Li Yang
- Xiangyang Wang
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Hunan Normal University, Hunan Provincial People's Hospital, Changsha, Hunan 410000, P.R. China, Department of Gastroenterology, The First Affiliated Hospital of Hunan Normal University, Hunan Provincial People's Hospital, Changsha, Hunan 410000, P.R. China
Published online on: June 7, 2024 https://doi.org/10.3892/ol.2024.14496
Article Number: 363
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary mantle cell lymphoma (MCL) in the gastrointestinal tract is rare, accounting for 4‑9% of all reported cases of gastrointestinal non‑Hodgkin lymphoma. Furthermore, involvement of the entire gastrointestinal tract in MCL is rare. The present report describes an example of MCL characterized by numerous diffuse polypoid lesions along the whole digestive tract. In particular, there was a focus on the endoscopic presentation of the digestive tract. The patient initially received a treatment regimen of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone. After two cycles of treatment, the regimen was changed to rituximab combined with etoposide, oxaliplatin and ifosfamide, with the addition of ibrutinib capsules. Patients with MCL have a poor prognosis; however, complete response can be achieved after treatment.

View Figures

View References

1	Castellino A, Tun AM, Wang Y, Habermann TM, King RL, Ristow KM, Cerhan JR, Inwards DJ, Paludo J, Ansell SM, et al: Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer J. 11:82021. View Article : Google Scholar : PubMed/NCBI
2	Lamm W, Dolak W, Kiesewetter B, Simonitsch-Klupp I, Puhr H and Raderer M: Gastrointestinal involvement in patients with mantle cell lymphoma: A single center experience of eighty-five patients. Dig Dis. 37:194–200. 2019. View Article : Google Scholar : PubMed/NCBI
3	Mohy-Ud-Din N, Guha A and Mitre M: Complete endoscopic and histopathological remission of mantle cell lymphoma of the gastrointestinal tract. Cureus. 11:e43502019.PubMed/NCBI
4	Zheng QF, Li JY, Qin L, Wei HM, Cai LY and Nong B: Gastrointestinal involvement by mantle cell lymphoma identified by biopsy performed during endoscopy: A case report. Medicine (Baltimore). 97:e97992018. View Article : Google Scholar : PubMed/NCBI
5	Huang PJ, Chang CL and Suk FM: Polypoid lesions from the oesophagus to colon. Gut. 67:5522018. View Article : Google Scholar : PubMed/NCBI
6	Maddocks K: Update on mantle cell lymphoma. Blood. 132:1647–1656. 2018. View Article : Google Scholar : PubMed/NCBI
7	Jain P and Wang M: Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 94:710–725. 2019. View Article : Google Scholar : PubMed/NCBI
8	Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J and Ladetto M; ESMO Guidelines Committee, : Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (Suppl 4):iv62–iv71. 2017. View Article : Google Scholar : PubMed/NCBI
9	Eyre TA, Bishton MJ, McCulloch R, O'Reilly M, Sanderson R, Menon G, Iyengar S, Lewis D, Lambert J, Linton KM, et al: Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 204:108–126. 2024. View Article : Google Scholar : PubMed/NCBI
10	Liu FD, Li XP, Xu XQ, Yu H, Luo PF and Zhou JY: Disease burden of non-Hodgkin lymphoma in Jiangsu Province from 1990 to 2019. Pract Prev Med. 30:284–287. 2023.(In Chinese).
11	Feng J, Fei Y, Gao M, Meng X, Zeng D, Zuo D, Ye H, Liang Y, Sun X, Liang R, et al: Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma. Hematol Oncol. 42:e32682024. View Article : Google Scholar : PubMed/NCBI
12	Mihăilă RG: Hepatitis C virus-Associated B cell non-Hodgkin's lymphoma. World J Gastroenterol. 22:6214–6223. 2016. View Article : Google Scholar : PubMed/NCBI
13	Mazzaro C, Bomben R, Gragnani L, Visentini M, Pozzato G, Pozzo F, Zucchetto A and Gattei V: Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy. Semin Hematol. 59:177–182. 2022. View Article : Google Scholar : PubMed/NCBI